June 2, 2020 / 5:07 AM / a month ago

BRIEF-Santhera Completes Reveragen's Extension Study With Vamorolone In Duchenne Muscular Dystrophy

June 2 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :

* SANTHERA ANNOUNCES COMPLETION OF REVERAGEN’S LONG-TERM EXTENSION STUDY WITH VAMOROLONE IN DUCHENNE MUSCULAR DYSTROPHY

* REVERAGEN HAS NOW OBTAINED SAFETY AND EFFICACY DATA WITH VAMOROLONE OVER A PERIOD OF 2.5 YEARS IN 41 BOYS WITH DMD

* VAMOROLONE WAS REPORTED TO BE SAFE AND WELL TOLERATED UP TO HIGHEST DOSE TESTED Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below